Cowen & Co. Maintains Their Buy Rating on Nucana Plc (NCNA)

By Austin Angelo

Cowen & Co. analyst Boris Peaker maintained a Buy rating on Nucana Plc (NASDAQ: NCNA) today. The company’s shares opened today at $23.88.

According to TipRanks.com, Peaker is a 5-star analyst with an average return of 14.7% and a 48.0% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.

Nucana Plc has an analyst consensus of Moderate Buy.

See today’s analyst top recommended stocks >>

The company has a one-year high of $32 and a one-year low of $9.32. Currently, Nucana Plc has an average volume of 32.55K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

NuCana Plc is a clinical-stage biopharmaceutical company, which engages in the development of technology platform for the treatment of patients with cancer. Its proprietary technology, ProTide, transforms chemotherapy agents and nucleoside analogs into medicines.